T. Rowe Price Associates
DARE icon

T. Rowe Price Associates’s Dare Bioscience DARE Stock Holding History

T. Rowe Price Associates’s Portfolio DARE Stock Details DARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29K Buy
13,318
+3,096
+30% +$6.92K ﹤0.01% 3214
2026
Q1 		$19K Hold
10,222
– – ﹤0.01% 3123
2025
Q4 		$20K Hold
10,222
– – ﹤0.01% 3079
2025
Q3 		$22K Hold
10,222
– – ﹤0.01% 3038
2025
Q2 		$25K Sell
10,222
-269
-3% -$785 ﹤0.01% 3043
2025
Q1 		$31K Hold
10,491
– – ﹤0.01% 2978
2024
Q4 		$33K Hold
10,491
– – ﹤0.01% 2969
2024
Q3 		$34K Buy
+10,491
New +$35.9K ﹤0.01% 2965
2024
Q2 		– Sell
-10,492
Closed -$62K – 2946
2024
Q1 		$62K Hold
10,492
– – ﹤0.01% 2846
2023
Q4 		$39K Hold
10,492
– – ﹤0.01% 2837
2023
Q3 		$59K Hold
10,492
– – ﹤0.01% 2754
2023
Q2 		$115K Hold
10,492
– – ﹤0.01% 2669
2023
Q1 		$131K Hold
10,492
– – ﹤0.01% 2634
2022
Q4 		$104K Hold
10,492
– – ﹤0.01% 2711
2022
Q3 		$126K Buy
10,492
+5,609
+115% +$77K ﹤0.01% 2669
2022
Q2 		$72K Hold
4,883
– – ﹤0.01% 2820
2022
Q1 		$87K Buy
+4,883
New +$92.3K ﹤0.01% 2870

Other funds holding DARE

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

T. Rowe Price Associates's DARE Position: Q2 2026 in Review

T. Rowe Price Associates increased its Dare Bioscience (DARE) stake by 30% in Q2 2026, buying an estimated $6.92K and bringing the position to 13,318 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #3214.

T. Rowe Price Associates first reported a position in DARE in Q1 2022 and has held it in 17 quarters since. The position peaked at $131K in Q1 2023. 27 funds tracked by Wall St. Rank hold DARE as of Q2 2026.

  • T. Rowe Price Associates held 13,318 shares of Dare Bioscience worth $29K as of Q2 2026.
  • T. Rowe Price Associates bought 3,096 Dare Bioscience shares in Q2 2026, an estimated $6.92K.
  • Dare Bioscience made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3214 holding.
  • T. Rowe Price Associates first reported a position in Dare Bioscience in Q1 2022 and has held it in 17 quarters since.
  • T. Rowe Price Associates's Dare Bioscience position peaked at $131K in Q1 2023.
  • 27 funds tracked by Wall St. Rank held Dare Bioscience as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.